（文章来源：证券日报） 证券日报网讯 12月30日，海特生物发布公告称，公司于2025年12月29日召开第九届董事会第六次会 议，审议通过了《关于变更部分募集资金用途及对部分募投项目结项并将节余募集资金永久补充流动资 金的议案》，拟将"高端原料药生产基地I期项目（API&CDMO）"予以结项，节余募集资金用于永久补 充流动资金，同时拟将募集资金投资项目"高端原料药研发中试项目"变更为"国家一类新药埃普奈明新 增适应症研究项目"，实施主体由"汉瑞药业（荆门）有限公司"变更为"武汉海特生物制药股份有限公 司"。 ...

Core Viewpoint - Hite Bio (300683.SZ) has approved changes to the use of part of its raised funds, including the completion of the "Phase I Project of High-end API Production Base (API&CDMO)" and reallocating surplus funds to permanently supplement working capital [1] Group 1 - The company has decided to conclude the "Phase I Project of High-end API Production Base (API&CDMO)" and will use the surplus funds for working capital [1] - The investment project "High-end API R&D Pilot Project" will be changed to "Research Project for New Indications of National Class I New Drug Epanutuzumab" [1] - The implementation entity for the project will be changed from "Hanrui Pharmaceutical (Jingmen) Co., Ltd." to "Wuhan Hite Bio Pharmaceutical Co., Ltd." [1]